Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque

Abstract

Cardiovascular events were higher after initiation of ICIs, potentially mediated by accelerated progression of atherosclerosis. Optimization of cardiovascular risk factors and increased awareness of cardiovascular risk before, during, and after treatment should be considered among patients on an ICI.